Drug
Dalbavancin clinical trials
Also written Dalvance.
- studies test it
- 23
- open now
- 2
- in phase 3
- 7
- first study started
- 2001
Keep track of what changes. Save the dalbavancin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
- Dalvance
- 12
Studies by the year they started
23 studies that test it; most in 2016 (4)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2008 | 1 |
| 2011 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 4 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 6
- Phase 3
- 7
- Phase 4
- 6
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 8
Durata Therapeutics Inc., an affiliate of Allergan plc (6) · AbbVie (3) · Allergan (3) · University of Colorado, Denver (2) · Centre Hospitalier Universitaire de Nice (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Infectious Diseases Physicians, Inc. (1) · Pfizer (1)
Studies
Open first, then newest update. How each study uses dalbavancin is read from its arms, and is right about nine times in ten.
Testing it · 23
- A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk LeukemiaRecruitingPhase 1St. Jude Children's Research HospitalNCT06810583Written as Dalbavancin
- Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic AnalysisRecruitingPhase 4University of Colorado, DenverNCT06266494Written as Dalbavancin
- Efficacy of Dalbavancin in Osteoarticular Infections Associated With Hip and Knee ReplacementsActive, not recruitingNot applicableCentre Hospitalier Universitaire de NiceNCT05046860Written as Dalbavancin
- DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus BacteremiaCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04775953Written as Dalbavancin
- Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSACompletedPhase 3AbbVieNCT02814916Written as Dalbavancin
- Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient TransitionTerminatedPhase 2/3University of Colorado, DenverNCT04847921Written as Dalbavancin
- Dalbavancin For The Treatment of Gram Positive Osteoarticular InfectionsCompletedPhase 4Infectious Diseases Physicians, Inc.NCT03426761Written as Dalbavancin
- Dalbavancin Outpatient PilotWithdrawnPhase 4Wake Forest University Health SciencesNCT03982030Written as Dalbavancin
- Hospital Avoidance Strategies for ABSSSITerminatedPhase 4Washington University School of MedicineNCT03372941Written as Dalbavancin
- Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective EndocarditisTerminatedPhase 2AbbVieNCT03148756Written as Dalbavancin
- Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial InfectionTerminatedPhase 1AbbVieNCT02688790Written as Dalbavancin
- Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)CompletedPhase 4AllerganNCT02961764Written as Dalbavancin
- Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)CompletedPhase 4AllerganNCT03233438Written as Dalbavancin
- Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With OsteomyelitisCompletedPhase 2Durata Therapeutics Inc., an affiliate of Allergan plcNCT02685033Written as Dalbavancin
- Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsCompletedPhase 3Durata Therapeutics Inc., an affiliate of Allergan plcNCT02127970Written as Dalbavancin
- Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With OsteomyelitisTerminatedPhase 2AllerganNCT03091439Written as Dalbavancin
- Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous OsteomyelitisWithdrawnPhase 3Durata Therapeutics International BV (an Affiliate of Actavis, Inc.)NCT02344511Written as Dalbavancin
- A P3 Comparator Trial in Community Acquired Bacterial PneumoniaWithdrawnPhase 3Durata Therapeutics Inc., an affiliate of Allergan plcNCT02269644Written as Dalbavancin
- A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.CompletedPhase 1Durata Therapeutics Inc., an affiliate of Allergan plcNCT01946568Written as Dalbavancin
- Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsCompletedPhase 3Durata Therapeutics Inc., an affiliate of Allergan plcNCT01431339Written as IV Dalbavancin
See all 23 studies that test dalbavancin →
As the comparator · 1 — what is tested is compared with dalbavancin
Codes
What other systems call dalbavancin · ClinicalTrials.gg INT004491
- MeSH (NLM) C469289dalbavancinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 808UI9MS5KDALBAVANCINConfirmed FDA, NLM, Wikidata
- RxNorm 1539239Confirmed FDA, Wikidata
- Wikidata Q5210237dalbavancinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C116741DalbavancinOne source FDA
- DrugBank DB06219One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C469289 | dalbavancin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 808UI9MS5K | DALBAVANCIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1539239 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5210237 | dalbavancin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C116741 | Dalbavancin | One source FDA |
| DrugBank | DB06219 | — | One source Wikidata |
Also registered as dalbavancin hydrochloride (UNII 33WDQ7T81E · RxNorm 1541465).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.